Earnings And Financial PerformanceCI reported 3Q25 earnings with adj EPS of $7.83, beating consensus by 2.5%.
Growth And RevenueSpecialty revenue was strong, coming in at $26.3B (up 10% YoY), driven by volume growth and adoption of biosimilars.
Regulatory ReformsThe introduction of a new rebate-free model is a big step in reducing the regulatory pressure that CI and other PBMs face.